



Innovative back microsurgery

Press release

VEXIM shares eligible for new *PEA-PME* savings plan

Toulouse, March 31, 2014 - VEXIM (FR0011072602 - ALVXM), a medical device company specializing in the minimally-invasive treatment of vertebral fractures, today confirms that its shares are eligible for the new “PEA-PME” SME equity savings plan.

VEXIM meets the eligibility criteria for “PEA-PME” SME equity savings plans in compliance with [Decree n°2014-283](#) issued on March 4, 2014 relating to the application of article 70 of the 2014 finance law n° 2013-1278: workforce of less than 5,000 employees on the one hand and annual revenues of less than €1,500m or a balance sheet of less than €2,000m, on the other hand.

Investors can include VEXIM shares in *PEA-PME* savings accounts, a new plan aimed at encouraging investments in small and mid-cap companies:

- identical terms and conditions for opening a new account as the existing equity savings plan (*PEA*) accounts;
- ceiling set at €75,000;
- individuals can hold *PEA-PME* savings account in a different financial institution than where they hold an existing *PEA* account;
- same tax incentives as *PEA* equity savings plan.

2014 preliminary financial agenda*:

Q1 2014 sales: April 15, 2014

H1 2014 sales: July 22, 2014

*Indicative dates, subject to potential modifications

About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital¹ and Banexi Venture, and from OSEO public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 57 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Argentina, India, Taiwan, Belgium, South Africa, Colombia, Panama and in the following countries where the product is currently being registered: Mexico, Brazil, Venezuela, Chile, Ecuador and Peru. VEXIM has been listed on NYSE Alternext Paris since May 3, 2012.

For further information, please go to www.vexim.com

¹ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.

SpineJack^{®2}, a revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack[®] lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack[®] range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack[®] technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029.

Contacts

VEXIM

Vincent Gardès

CEO

Jérôme Marzinski

Deputy CEO

Tel: +33 5 61 48 48 38

shareholders@vexim.com

NewCap.

Financial Communications
and Investor Relations

Dusan Oresansky /

Emmanuel Huynh

Tel: +33 1 44 71 94 92

vexim@newcap.fr

Alize RP

Press Relations

Caroline Carmagnol

vexim@alizerp.com

Tel: +33 1 70 22 53 90 /

+33 6 64 18 99 59



- **Name:** VEXIM
- **ISIN code:** FR0011072602
- **Ticker:** ALVXM

² This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.